【作者】 段升军；

【导师】 张清泉；

【作者基本信息】 山东大学 ， 普通外科， 2006， 硕士

【摘要】 目的：检测胰腺癌患者组织中ICAM-1和VCAM-1蛋白表达以及对胰腺癌患者血清中可溶性细胞间粘附分子(sICAM-1)和可溶性血管细胞粘附分子(sVCAM-1)含量进行测定，探讨二者与胰腺癌侵袭转移生物学特性之间的关系，以明确胰腺癌的侵袭转移机制，为在分子水平抗粘附作用、预防胰腺癌复发提供理论依据。同时对胰腺癌的治疗效果、预后判断进行客观评估。 方法：对32例胰腺癌组织、17例慢性胰腺炎组织、21例正常胰腺组织标本进行了ICAM-1及VCAM-1免疫组化染色，分析ICAM-1及VCAM-1的表达与胰腺癌患者临床病理指标及预后的关系。用酶联免疫吸附试验对25例术前及化疗前未作任何治疗，术后一周及化疗后一周未发生并发症的胰腺癌患者外周血进行sICAM-1和sVCAM-1含量的检测，分析外周血清中sICAM-1和sVCAM-1手术前后以及化疗前后含量的变化，同时对胰腺癌患者外周血清中CEA、CA19-9的含量进行检测。 结果一(免疫组化) 1．胰腺癌组织ICAM-1的阳性表达率为84.4％，慢性胰腺炎组织表达率为52.9％，在正常胰腺组织为19.0％。胰腺癌组织ICAM-1表达显著高于慢性胰腺炎组织及正常胰腺组织(P＜0.05；P＜0.01)。 2．胰腺癌组织VCAM-1的阳性表达率为78.1％，慢性胰腺炎组织表达率为47.1％，在正常胰腺组织为14.3％。胰腺癌组织VCAM-1表达显著高于慢性胰腺炎组织及正常胰腺组织(P＜0.05；P＜0.01)。 3．慢性胰腺炎组织ICAM-1及VCAM-1的表达显著高于正常胰腺组织(P＜0.01；P＜0.05)。 4．胰腺癌组织中ICAM-1和VCAM-1的表达成相关关系(r=0.472，P＜0.01)。 5．胰腺癌组织中ICAM-1及VCAM-1表达水平与患者年龄、性别、肿瘤大小、位置、病理学分级无关(P＞0.05)，与肿瘤分期及有无远处转移有关(P＜0.05)。更多还原

【Abstract】 Objective:To detect the expressions of ICAM-1 and VCAM-1 in pancreatic cancer tissues,measure the serum soluble intercellular adhesion molecular-1(sICAM-l) and soluble vascular cell adhesion molecular-1(sVCAM-l) in patients with pancreatic cancer,study their relations to the biological characterization of pancreatic cancer,to clarify the role of ICAM-1 and VCAM-1 in the invasion and metastasis of pancreatic cancer and anti-adhesion on molecules to pancreatic cancer,to prevent recurrence and metastasis of pancreatic cancer,to get an objective therapeutic evaluation and judgment of prognosis for patients with pancreatic cancer.Methods:Specimens from 32 pancreatic cancer patients, 17 pancreatitis patients,21 normal tissues,image analysis with the methods of immunohistochemistry followed.Analysis the correlation between their expressions and clinic pathologic features and prognostic of pancreatic cancer patients.ELSIA technique was used to measure serum concentration of sICAM-1 and sVCAM-1 in 25 patients with pancreatic cancer without treatment before operation or chemotherapy in the same patients without complication one week later after operation or chemotherapy.The changes of serum sICAM-1 and sVCAM-1 level were analyzed pre-operation and post-operation,pre-chemotherapy and post-chemotherapy.Meanwhile the serum CEA and CA19-9 of 25 pancreatic cancer patients were tested.Result one(immunohistochemistry)1.The positive expression of ICAM-1 was 84.4% in pancreatic cancer tissues and 52.9% in chronic pancreatitis tissues and 19.0% in normal pancreatic tissues.The expression of ICAM-1 in pancreatic cancer tissues was significantly higher than that in chronic pancreatitis tissues and in normal control group(P<0.05;P<0.01).2.25 out of 32(78.1%) tissues of pancreatic cancer had the expression of VCAM-1,8 out of 17(47.1%) tissues in patients with chronic pancreatitis had the expression of更多还原